Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 2012 May 15;18(10):2922-9
Date
03/29/2012Pubmed ID
22452943Pubmed Central ID
PMC4176886DOI
10.1158/1078-0432.CCR-11-2217Scopus ID
2-s2.0-84861133847 (requires institutional sign-in at Scopus site) 74 CitationsAbstract
PURPOSE: To determine whether the Royal Marsden Hospital (RMH; London, UK) prognostic score for phase I patients can be validated in a large group of individuals seen in a different center and whether other prognostic variables are also relevant, we present an analysis of 1,181 patients treated in the MD Anderson Cancer Center (MDACC; Houston, TX) phase I clinic.
EXPERIMENTAL DESIGN: Medical records of 1,181 consecutive patients who were treated on at least one trial in the phase I clinic were reviewed.
RESULTS: The median age was 58 years and 50% were women. The median number of prior therapies was four and median survival 10 months [95% confidence interval (CI), 9.1-10.9 months]. Independent factors that predicted shorter survival in a multivariate Cox model and could be internally validated included RMH score of >1 (P < 0.0001; albumin <3.5 g/dL; lactate dehydrogenase >upper limit of normal, and >two sites of metastases), gastrointestinal tumor type (P < 0.0001), and Eastern Cooperative Oncology Group performance status ≥ 1 (P = 0.0004). The median survival was 24.0, 15.2, 8.4, 6.2, and 4.1 months for patients with 0, 1, 2, 3, and 4 or 5 of the above risk factors, respectively.
CONCLUSION: The RMH score was validated in a large group of patients at MDACC. Internal validation of the independent prognostic factors for survival led to the development of the MDACC prognostic score, a modification of the RMH score that strengthens it.
Author List
Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Aged, 80 and over
Child
Child, Preschool
Clinical Trials, Phase I as Topic
Female
Gastrointestinal Neoplasms
Humans
Liver Neoplasms
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasms
Prognosis
Risk Factors
Survival Rate
Treatment Outcome
Young Adult
